Alpha Cognition Inc
ACOG
Rankning i aktier
#20221
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aktiekurs
$8.45
Marknadsvärde
$131.24M
Förändring (1 dag)
3.17%
Förändring (1 år)
67.99%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategori
Healthcare
EPS för Alpha Cognition Inc (ACOG)
EPS per June 2026 TTM: $-0.40
Enligt Alpha Cognition Incs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) $-0.40. Vid slutet av 2022 hade bolaget ett EPS på $-0.18, en minskning jämfört med EPS från 2021 som var $-0.37.
EPS-historik för Alpha Cognition Inc från 2018 till 2026
EPS vid slutet av varje år
| År | EPS | Ändra |
|---|---|---|
| 2026 (TTM) | $-0.40 | 166.67% |
| 2023 | $-0.15 | -16.67% |
| 2022 | $-0.18 | -51.35% |
| 2021 | $-0.37 | -61.46% |
| 2020 | $-0.96 | 357.14% |
| 2019 | $-0.21 | 672.06% |
| 2018 | $-0.03 | 0.00% |
EPS för liknande företag eller konkurrenter
| Företag | EPS | EPS-differens | Land |
|---|---|---|---|
| $17.32 | -4,430.00% |
US
|
|
| $-7.98 | 1,895.00% |
US
|
|
| $-5.29 | 1,222.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,035.00% |
NL
|
